Hypothesis

Chronic mTORC1 activation in aged fibroblasts drives a dual hit on the extracellular matrix: it silences HAS2 transcription and blocks autophagic clearance of low-molecular-weight hyaluronan (LMW-HA), shifting HA from a protective high-molecular-weight (HMW-HA) scaffold to an inflammatory ligand. Conversely, mTORC1 inhibition restores HA homeostasis by (1) reactivating FOXO-dependent HAS2 expression and (2) boosting TFEB-mediated lysosomal biogenesis that degrades LMW-HA fragments. This positions mTORC1 not merely as a growth switch but as a gatekeeper of the glycocalyx that toggles between civilizational tissue maintenance and survival-mode matrix degradation.

Mechanistic Reasoning

mTORC1 phosphorylates and inhibits the transcription factor FOXO1/3, preventing their nuclear entry and thus repressing HAS2 promoter activity [2]. Simultaneously, mTORC1 suppresses TFEB activity through phosphorylation by S6K1, keeping TFEB cytosolic and impairing lysosomal gene expression and autophagic flux [1]. In aging, persistent mTORC1 signaling therefore reduces HMW-HA synthesis while allowing LMW-HA to accumulate, where it engages CD44/RHAMM to trigger NF-kB-mediated inflammation [3]. The resulting inflammatory milieu further activates mTORC1 via TLR2/4-MyD88 signaling, creating a vicious cycle that locks fibroblasts in a survival-mode, matrix-degrading state.

Testable Predictions

1. Rapamycin (or torin1) treatment of aged human dermal fibroblasts will increase nuclear FOXO1/3, raise HAS2 mRNA and protein, and elevate secreted HMW-HA within 48 h.
2. The same treatment will enhance TFEB nuclear localization, increase LC3-II conversion and lysosomal LAMP1 levels, and accelerate degradation of exogenously added LMW-HA (measured by a fluorescence-quenching assay).
3. Silencing FOXO1/3 with siRNA will blunt the rapamycin-induced rise in HAS2 and HMW-HA, whereas TFEB knock-down will abolish the clearance of LMW-HA despite mTORC1 inhibition.
4. Combining rapamycin with lysosomal inhibition (chloroquine) will prevent the reduction of LMW-HA and the associated decline in IL-6 secretion, indicating that HA fragment removal is autophagy-dependent.

Experimental Approach

• Culture fibroblasts from young (<=30 y) and old (>65 y) donors.
• Treat with rapamycin (100 nM) or vehicle for 24-48 h.
• Measure FOXO1/3 and TFEB subcellular localization by immunofluorescence.
• Quantify HAS2 mRNA (qPCR) and protein (Western), HA size distribution by HPLC-SEC, and secreted HMW-HA by ELISA.
• Assess autophagic flux (LC3-II/p62) and lysosomal activity (LysoTracker).
• Add fluorescent LMW-HA, track degradation over time.
• Use siRNA against FOXO1/3, TFEB, or scramble control.
• Read out inflammatory cytokines (IL-6, IL-8) via ELISA.

Implications

If validated, this hypothesis would reposition mTORC1 inhibition as a strategy to rebuild the glycocalyx barrier, decoupling the longevity trade-off of 'civilization versus survival' into a controllable switch that promotes tissue-level maintenance without compromising cellular survival pathways. It also suggests that HA-based biomarkers (HMW-HA/LMW-HA ratio) could serve as pharmacodynamic readouts for mTOR-targeted gerotherapeutics.